Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2017

Open Access 01-12-2017 | Review

Ion channels or aquaporins as novel molecular targets in gastric cancer

Authors: Jianling Xia, Hongqiang Wang, Shi Li, Qinghui Wu, Li Sun, Hongxiang Huang, Ming Zeng

Published in: Molecular Cancer | Issue 1/2017

Login to get access

Abstract

Gastric cancer (GC) is a common disease with few effective treatment choices and poor prognosis, and has the second-highest mortality rates among all cancers worldwide. Dysregulation and/or malfunction of ion channels or aquaporins (AQPs) are common in various human cancers. Furthermore, ion channels are involved in numerous important aspects of the tumor aggressive phonotype, such as proliferation, cell cycle, apoptosis, motility, migration, and invasion. Indeed, by localizing in the plasma membrane, ion channels or AQPs can sense and respond to extracellular environment changes; thus, they play a crucial role in cell signaling and cancer progression. These findings have expanded a new area of pharmaceutical exploration for various types of cancer, including GC. The involvement of multiple ion channels, such as voltage-gated potassium and sodium channels, intracellular chloride channels, ‘transient receptor potential’ channels, and AQPs, which have been shown to facilitate the pathogenesis of other tumors, also plays a role in GC. In this review, an overview of ion channel and aquaporin expression and function in carcinogenesis of GC is presented. Studies of ion channels or AQPs will advance our understanding of the molecular genesis of GC and may identify novel and effective targets for the clinical application of GC.
Literature
1.
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
3.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
4.
Arnold M, Moore SP, Hassler S, Ellison-Loschmann L, Forman D, Bray F. The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut. 2014;63:64–71.CrossRefPubMed
5.
6.
Riquelme I, Tapia O, Leal P, Sandoval A, Varga MG, Letelier P, et al. miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordr). 2016;39:23–33.CrossRef
7.
Lim SM, Lim JY, Cho JY. Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome. World J Gastroenterol. 2014;20:2042–50.CrossRefPubMedPubMedCentral
8.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2012 [cited 2016 January 25]. http://​globocan.​ iarc.fr.
9.
10.
Hoffmann EK, Holm NB, Lambert IH. Functions of volume-sensitive and calcium-activated chloride channels. IUBMB Life. 2014;66:257–67.CrossRefPubMed
11.
Lang F, Ritter M, Völkl H, Häussinger D. The biological significance of cell volume. Ren Physiol Biochem. 1993;16:48–65.PubMed
12.
Kondratskyi A, Kondratska K, Skryma R, Prevarskaya N. Ion channels in the regulation of apoptosis. Biochim Biophys Acta. 1848;2015:2532–46.
13.
14.
15.
Pedersen SF, Stock C. Ion channels and transporters in cancer: pathophysiology, regulation, and clinical potential. Cancer Res. 2013;73:1658–61.CrossRefPubMed
16.
Munaron L, Arcangeli A. Editorial: ion fluxes and cancer. Recent Pat Anticancer Drug Discov. 2013;8:1–3.CrossRefPubMed
17.
Hille B. Ion Channels of Excitable Membranes. 3rd ed. Sunderland, Mass: Sinauer; 2001.
18.
19.
Niemeyer BA, Mery L, Zawar C, Suckow A, Monje F, Pardo LA, et al. Ion channels in health and disease. 83rd Boehringer Ingelheim Fonds International Titisee Conference. EMBO Rep. 2001;2:568–73.CrossRefPubMedPubMedCentral
20.
21.
Zhang P, Yang X, Yin Q, Yi J, Shen W, Zhao L, et al. Inhibition of SK4 potassium channels suppresses cell proliferation, migration and the epithelial-mesenchymal transition in triple-negative breast cancer cells. PLoS One. 2016;11:e0154471.CrossRefPubMedPubMedCentral
22.
Liu H, Huang J, Peng J, Wu X, Zhang Y, Zhu W, et al. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway. Mol Cancer. 2015;14:59.CrossRefPubMedPubMedCentral
23.
Zhang GM, Wan FN, Qin XJ, Cao DL, Zhang HL, Zhu Y, et al. Prognostic significance of the TREK-1 K2P potassium channels in prostate cancer. Oncotarget. 2015;6:18460–8.CrossRefPubMedPubMedCentral
24.
Lee JH, Park JW, Byun JK, Kim HK, Ryu PD, Lee SY, et al. Silencing of voltage-gated potassium channel Kv9.3 inhibits proliferation in human colon and lung carcinoma cells. Oncotarget. 2015;6:8132–43.CrossRefPubMedPubMedCentral
25.
Ding XW, Yang WB, Gao S, Wang W, Li Z, Hu WM, et al. Prognostic significance of hERG1 expression in gastric cancer. Dig Dis Sci. 2010;55:1004–10.CrossRefPubMed
26.
Crociani O, Lastraioli E, Boni L, Pillozzi S, Romoli MR, D’Amico M, et al. hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implications. Clin Cancer Res. 2014;20:1502–12.CrossRefPubMed
27.
Shao XD, Wu KC, Guo XZ, Xie MJ, Zhang J, Fan DM. Expression and significance of HERG protein in gastric cancer. Cancer Biol Ther. 2008;7:45–50.CrossRefPubMed
28.
Zhang R, Tian P, Chi Q, Wang J, Wang Y, Sun L, et al. Human ether-à-go-go-related gene expression is essential for cisplatin to induce apoptosis in human gastric cancer. Oncol Rep. 2012;27:433–40.PubMed
29.
Lee I, Park C, Kang WK. Knockdown of inwardly rectifying potassium channel Kir2.2 suppresses tumorigenesis by inducing reactive oxygen species-mediated cellular senescence. Mol Cancer Ther. 2010;9:2951–9.CrossRefPubMed
30.
Kim HJ, Jang SH, Jeong YA, Ryu PD, Kim DY, Lee SY. Involvement of Kv4.1 K(+) channels in gastric cancer cell proliferation. Biol Pharm Bull. 2010;33:1754–7.CrossRefPubMed
31.
Liu SI, Chi CW, Lui WY, Mok KT, Wu CW, Wu SN. Correlation of hepatocyte growth factor-induced proliferation and calcium-activated potassium current in human gastric cancer cells. Biochim Biophys Acta. 1998;1368:256–66.CrossRefPubMed
32.
Zhang J, Zhao Z, Zu C, Hu H, Shen H, Zhang M, et al. Atrial natriuretic peptide modulates the proliferation of human gastric cancer cells via KCNQ1 expression. Oncol Lett. 2013;6:407–14.PubMedPubMedCentral
33.
Bielanska J, Hernández-Losa J, Pérez-Verdaguer M, Moline T, Somoza R, Ramón Y, Cajal S, et al. Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer. Curr Cancer Drug Targets. 2009;9:904–14.CrossRefPubMed
34.
Jentsch TJ, Stein V, Weinreich F, Zdebik AA. Molecular Structure and Physiological Function of Chloride Channels. Physiol Rev. 2002;82:503–68.CrossRefPubMed
35.
Xu B, Jin X, Min L, Li Q, Deng L, Wu H, et al. Chloride channel-3 promotes tumor metastasis by regulating membrane ruffling and is associated with poor survival. Oncotarget. 2015;6:2434–50.CrossRefPubMed
36.
Yang L, Ye D, Ye W, Jiao C, Zhu L, Mao J, et al. ClC-3 is a main component of background chloride channels activated under isotonic conditions by autocrine ATP in nasopharyngeal carcinoma cells. J Cell Physiol. 2011;226:2516–26.CrossRefPubMed
37.
Britschgi A, Bill A, Brinkhaus H, Rothwell C, Clay I, Duss S, et al. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc Natl Acad Sci U S A. 2013;110:E1026–34.CrossRefPubMedPubMedCentral
38.
Jia L, Liu W, Guan L, Lu M, Wang K. Inhibition of calcium-activated chloride channel ANO1/TMEM16A suppresses tumor growth and invasion in human lung cancer. PLoS One. 2015;10:e0136584.CrossRefPubMedPubMedCentral
39.
Wang P, Zeng Y, Liu T, Zhang C, Yu PW, Hao YX, et al. Chloride intracellular channel 1 regulates colon cancer cell migration and invasion through ROS/ERK pathway. World J Gastroenterol. 2014;20:2071–8.CrossRefPubMedPubMedCentral
40.
Lu J, Dong Q, Zhang B, Wang X, Ye B, Zhang F, et al. Chloride intracellular channel 1 (CLIC1) is activated and functions as an oncogene in pancreatic cancer. Med Oncol. 2015;32:616.PubMed
41.
Hosogi S, Kusuzaki K, Inui T, Wang X, Marunaka Y. Cytosolic chloride ion is a key factor in lysosomal acidification and function of autophagy in human gastric cancer cell. J Cell Mol Med. 2014;18:1124–33.CrossRefPubMedPubMedCentral
42.
Chen CD, Wang CS, Huang YH, Chien KY, Liang Y, Chen WJ, et al. Overexpression of CLIC1 in human gastric carcinoma and its clinicopathological significance. Proteomics. 2007;7:155–67.CrossRefPubMed
43.
Zheng DL, Huang QL, Zhou F, Huang QJ, Lin JY, Lin X. PA28β regulates cell invasion of gastric cancer via modulating the expression of chloride intracellular channel. J Cell Biochem. 2012;113:1537–46.PubMed
44.
Zhao W, Lu M, Zhang Q. Chloride intracellular channel 1 regulates migration and invasion in gastric cancer by triggering the ROS-mediated p38 MAPK signaling pathway. Mol Med Rep. 2015;12:8041–7.PubMedPubMedCentral
45.
46.
Liu F, Cao QH, Lu DJ, Luo B, Lu XF, Luo RC, et al. TMEM16A overexpression contributes to tumor invasion and poor prognosis of human gastric cancer through TGF-β signaling. Oncotarget. 2015;6:11585–99.CrossRefPubMedPubMedCentral
47.
Mazzone A, Gibbons SJ, Bernard CE, Nowsheen S, Middha S, Almada LL, et al. Identification and characterization of a novel promoter for the human ANO1 gene regulated by the transcription factor signal transducer and activator of transcription 6 (STAT6). FASEB J. 2015;29:152–63.CrossRefPubMed
48.
Owsianik G, D’hoedt D, Voets T, Nilius B. Structure-function relationship of the TRP channel superfamily. Rev Physiol Biochem Pharmacol. 2006;156:61–90.PubMed
49.
Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev. 2007;87:165–217.CrossRefPubMed
50.
Shapovalov G, Ritaine A, Skryma R, Prevarskaya N. Role of TRP ion channels in cancer and tumorigenesis. Semin Immunopathol. 2016;38:357–69.CrossRefPubMed
51.
Middelbeek J, Kuipers AJ, Henneman L, Visser D, Eidhof I, van Horssen R, et al. TRPM7 is required for breast tumor cell metastasis. Cancer Res. 2012;72:4250–61.CrossRefPubMed
52.
Monet M, Lehen’kyi V, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M, et al. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res. 2010;70:1225–35.CrossRefPubMed
53.
Ding X, He Z, Zhou K, Cheng J, Yao H, Lu D, et al. Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. J Natl Cancer Inst. 2010;102:1052–68.CrossRefPubMed
54.
Bhardwaj R, Hediger MA, Demaurex N. Redox modulation of STIM-ORAI signaling. Cell Calcium. 2016.
55.
Schmidt S, Liu G, Liu G, Yang W, Honisch S, Pantelakos S, et al. Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells. Oncotarget. 2014;5:4799–810.CrossRefPubMedPubMedCentral
56.
Yang S, Zhang JJ, Huang XY. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell. 2009;15:124–34.CrossRefPubMed
57.
Kim BJ, Kim SY, Lee S, Jeon JH, Matsui H, Kwon YK, et al. The role of transient receptor potential channel blockers in human gastric cancer cell viability. Can J Physiol Pharmacol. 2012;90:175–86.CrossRefPubMed
58.
Kim BJ, Park EJ, Lee JH, Jeon JH, Kim SJ, So I. Suppression of transient receptor potential melastatin 7 channel induces cell death in gastric cancer. Cancer Sci. 2008;99:2502–9.CrossRefPubMed
59.
Chow J, Norng M, Zhang J, Chai J. TRPV6 mediates capsaicin-induced apoptosis in gastric cancer cells—Mechanisms behind a possible new “hot”cancer treatment. Biochim Biophys Acta. 2007;1773:565–76.CrossRefPubMed
60.
Cai R, Ding X, Zhou K, Shi Y, Ge R, Ren G, et al. Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells. Int J Cancer. 2009;125:2281–7.CrossRefPubMed
61.
Xia J, Wang H, Huang H, Sun L, Dong S, Huang N, Shi M, et al. Elevated Orai1 and STIM1 expressions upregulate MACC1 expression to promote tumor cell proliferation, metabolism, migration, and invasion in human gastric cancer. Cancer Lett. 2016;381:31–40.CrossRefPubMed
62.
Catterall WA. Cellular and molecular biology of voltage-gated sodium channels. Physiol Rev. 1992;72:S15–48.PubMed
63.
Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 2000;26:13–25.CrossRefPubMed
64.
65.
Black JA, Newcombe J, Waxman SG. Nav1.5 sodium channels in macrophages in multiple sclerosis lesions. Mult Scler. 2013;19:532–42.CrossRefPubMed
66.
Brackenbury WJ, Djamgoz MB, Isom LL. An emerging role for voltage-gated Na + channels in cellular migration: Regulation of central nervous system development and potentiation of invasive cancers. Neuroscientist. 2008;14:571–83.CrossRefPubMedPubMedCentral
67.
Andrikopoulos P, Fraser SP, Patterson L, Ahmad Z, Burcu H, Ottaviani D, et al. Angiogenic functions of voltage-gated Na + channels in human endothelial cells: modulation of vascular endothelial growth factor (VEGF) signaling. J Biol Chem. 2011;286:16846–60.CrossRefPubMedPubMedCentral
68.
Chatelier A, Mercier A, Tremblier B, Thériault O, Moubarak M, Benamer N, et al. A distinct de novo expression of Nav1.5 sodium channels in human atrial fibroblasts differentiated into myofibroblasts. J Physiol. 2012;590:4307–19.CrossRefPubMedPubMedCentral
69.
Brackenbury WJ. Voltage-gated sodium channels and metastatic disease. Channels (Austin). 2012;6:352–61.CrossRef
70.
House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, Luu T, et al. Voltage-gated Na + channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. Cancer Res. 2010;70:6957–67.CrossRefPubMedPubMedCentral
71.
Campbell TM, Main MJ, Fitzgerald EM. Functional expression of the voltage-gated Na(+)-channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells. J Cell Sci. 2013;126:4939–49.CrossRefPubMed
72.
Hernandez-Plata E, Ortiz CS, Marquina-Castillo B, Medina-Martinez I, Alfaro A, Berumen J, et al. Overexpression of NaV 1.6 channels is associated with the invasion capacity of human cervical cancer. Int J Cancer. 2012;130:2013–23.CrossRefPubMed
73.
Xia J, Huang N, Huang H, Sun L, Dong S, Su J, et al. Voltage-gated sodium channel Nav1.7 promotes gastric cancer progression through MACC1-mediated upregulation of NHE1. Int J Cancer. 2016;139:2553–69.CrossRefPubMed
74.
75.
Magni F, Sarto C, Ticozzi D, Soldi M, Bosso N, Mocarelli P, et al. Proteomic knowledge of human aquaporins. Proteomics. 2006;6:5637–49.CrossRefPubMed
76.
77.
Chen J, Wang Z, Xu D, Liu Y, Gao Y. Aquaporin 3 promotes prostate cancer cell motility and invasion via extracellular signal-regulated kinase 1/2-mediated matrix metalloproteinase-3 secretion. Mol Med Rep. 2015;11:2882–8.PubMed
78.
Yang L, Wang X, Zhen S, Zhang S, Kang D, Lin Z. Aquaporin-4 upregulated expression in glioma tissue is a reaction to glioma-associated edema induced by vascular endothelial growth factor. Oncol Rep. 2012;28:1633–8.PubMed
79.
Jung HJ, Park JY, Jeon HS, Kwon TH. Aquaporin-5: a marker protein for proliferation and migration of human breast cancer cells. PLoS One. 2011;6:e28492.CrossRefPubMedPubMedCentral
80.
Shi YH, Rehemu N, Ma H, Tuokan T, Chen R, Suzuke L. Increased migration and local invasion potential of SiHa cervical cancer cells expressing Aquaporin 8. Asian Pac J Cancer Prev. 2013;14:1825–8.CrossRefPubMed
81.
Chen J, Wang T, Zhou YC, Gao F, Zhang ZH, Xu H, et al. Aquaporin 3 promotes epithelial-mesenchymal transition in gastric cancer. J Exp Clin Cancer Res. 2014;33:38.CrossRefPubMedPubMedCentral
82.
Li Z, Li B, Zhang L, Chen L, Sun G, Zhang Q, et al. The proliferation impairment induced by AQP3 deficiency is the result of glycerol uptake and metabolism inhibition in gastric cancer cells. Tumour Biol. 2016;37:9169–79.CrossRefPubMed
83.
Wang J, Gui Z, Deng L, Sun M, Guo R, Zhang W, et al. c-Met upregulates aquaporin 3 expression in human gastric carcinoma cells via the ERK signalling pathway. Cancer Lett. 2012;319:109–17.CrossRefPubMed
84.
Jiang B, Li Z, Zhang W, Wang H, Zhi X, Feng J, et al. miR-874 Inhibits cell proliferation, migration and invasion through targeting aquaporin-3 in gastric cancer. J Gastroenterol. 2014;49:1011–25.CrossRefPubMed
85.
Huang Y, Zhu Z, Sun M, Wang J, Guo R, Shen L, et al. Critical role of aquaporin-3 in the human epidermal growth factor-induced migration and proliferation in the human gastric adenocarcinoma cells. Cancer Biol Ther. 2010;9:1000–7.CrossRefPubMed
86.
Huang YH, Zhou XY, Wang HM, Xu H, Chen J, Lv NH. Aquaporin 5 promotes the proliferation and migration of human gastric carcinoma cells. Tumour Biol. 2013;34:1743–51.CrossRefPubMed
87.
Watanabe T, Fujii T, Oya T, Horikawa N, Tabuchi Y, Takahashi Y, et al. Involvement of aquaporin-5 in differentiation of human gastric cancer cells. J Physiol Sci. 2009;59:113–22.CrossRefPubMed
88.
Jang SH, Choi SY, Ryu PD, Lee SY. Anti-proliferative effect of Kv1.3 blockers in A549 human lung adenocarcinoma in vitro and in vivo. Eur J Pharmacol. 2011;651:26–32.CrossRefPubMed
89.
Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, et al. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis. 2014;35:2787–97.CrossRefPubMed
90.
Nelson M, Yang M, Dowle AA, Thomas JR, Brackenbury WJ. The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis. Mol Cancer. 2015;14:13.CrossRefPubMedPubMedCentral
91.
Setti M, Savalli N, Osti D, Richichi C, Angelini M, Brescia P, et al. Functional role of CLIC1 ion channel in glioblastoma-derived stem/progenitor cells. J Natl Cancer Inst. 2013;105:1644–55.CrossRefPubMedPubMedCentral
92.
Soveral G, Casini A. Aquaporin modulators: a patent review (2010–2015). Expert Opin Ther Pat. 2017;27:49–62.CrossRefPubMed
93.
de Almeida A, Soveral G, Casini A. Gold compounds as aquaporin inhibitors: new opportunities for therapy and imaging. Med Chem Commun. 2014;5:1444–53.CrossRef
94.
Chulso M, David M. Aquaporins in health and disease: new molecular targets for drug discovery. In: Graca S, Soren N, Angela C, editors. Aquaporins in carcinogenesis: water and glycerol channels as new potential drug targets. Boca Raton: CRC Press; 2015. p. 217–32.
95.
Dorward HS, Du A, Bruhn MA, Wrin J, Pei JV, Evdokiou A, et al. Pharmacological blockade of aquaporin-1 water channel by AqB013 restricts migration and invasiveness of colon cancer cells and prevents endothelial tube formation in vitro. J Exp Clin Cancer Res. 2016;35:36.CrossRefPubMedPubMedCentral
96.
Liu W, Wang K, Gong K, Li X, Luo K. Epidermal growth factor enhances MPC-83 pancreatic cancer cell migration through the upregulation of aquaporin 3. Mol Med Rep. 2012;6:607–10.PubMed
97.
Dong X, Wang Y, Zhou Y, Wen J, Wang S, Shen L. Aquaporin 3 facilitates chemoresistance in gastric cancer cells to cisplatin via autophagy. Cell Death Discov. 2016;2:16087.CrossRefPubMedPubMedCentral
98.
Ge R, Tai Y, Sun Y, Zhou K, Yang S, Cheng T, et al. Critical role of TRPC6 channels in VEGF-mediated angiogenesis. Cancer Lett. 2009;283:43–51.CrossRefPubMed
99.
Brackenbury WJ, Djamgoz MBA. Nerve growth factor enhances voltage-gated Na + channel activity and transwell migration in Mat-LyLu rat prostate cancer cell line. J Cell Physiol. 2007;210:602–8.CrossRefPubMedPubMedCentral
100.
Kessler W, Budde T, Gekle M, Fabian A, Schwab A. Activation of cell migration with fibroblast growth factor-2 requires calcium-sensitive potassium channels. Pflugers Arch. 2008;456:813–23.CrossRefPubMed
101.
Chodon D, Guilbert A, Dhennin-Duthille I, Gautier M, Telliez MS, Sevestre H, et al. Estrogen regulation of TRPM8 expression in breast cancer cells. BMC Cancer. 2010;10:212.CrossRefPubMedPubMedCentral
102.
Lilja J, Laulund F, Forsby A. Insulin and insulin-like growth factor type-I up-regulate the vanilloid receptor-1 (TRPV1) in stably TRPV1-expressing SH-SY5Y neuroblastoma cells. J Neurosci Res. 2007;85:1413–9.CrossRefPubMed
Metadata
Title
Ion channels or aquaporins as novel molecular targets in gastric cancer
Authors
Jianling Xia
Hongqiang Wang
Shi Li
Qinghui Wu
Li Sun
Hongxiang Huang
Ming Zeng
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2017
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-017-0622-y

Other articles of this Issue 1/2017

Molecular Cancer 1/2017 Go to the issue

Research

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models

Research

MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway

Research

BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma

Research

LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation

Research

IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis

Review

Circular RNAs in human cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits